IL172496A - Encoding Nucleic Acid Sequences and Compounds Containing IgE and / or 15-IL Peptide and Methods for Their Use - Google Patents

Encoding Nucleic Acid Sequences and Compounds Containing IgE and / or 15-IL Peptide and Methods for Their Use

Info

Publication number
IL172496A
IL172496A IL172496A IL17249605A IL172496A IL 172496 A IL172496 A IL 172496A IL 172496 A IL172496 A IL 172496A IL 17249605 A IL17249605 A IL 17249605A IL 172496 A IL172496 A IL 172496A
Authority
IL
Israel
Prior art keywords
protein
nucleic acid
ige
cells
sequence
Prior art date
Application number
IL172496A
Other languages
English (en)
Hebrew (he)
Other versions
IL172496A0 (en
Inventor
David B Weiner
Michele Kutzler
Andrew K Choo
Joo-Sung Yang
Jean D Boyer
Original Assignee
Univ Pennsylvania
David B Weiner
Michele Kutzler
Andrew K Choo
Joo-Sung Yang
Jean D Boyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, David B Weiner, Michele Kutzler, Andrew K Choo, Joo-Sung Yang, Jean D Boyer filed Critical Univ Pennsylvania
Publication of IL172496A0 publication Critical patent/IL172496A0/en
Publication of IL172496A publication Critical patent/IL172496A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL172496A 2003-06-13 2005-12-11 Encoding Nucleic Acid Sequences and Compounds Containing IgE and / or 15-IL Peptide and Methods for Their Use IL172496A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47820503P 2003-06-13 2003-06-13
US47821003P 2003-06-13 2003-06-13
PCT/US2004/018962 WO2005000235A2 (fr) 2003-06-13 2004-06-14 Codage de sequences nucleotidiques et compositions comprenant un peptide signal ige et/ou un il-15 et procedes d'utilisation

Publications (2)

Publication Number Publication Date
IL172496A0 IL172496A0 (en) 2006-04-10
IL172496A true IL172496A (en) 2013-02-28

Family

ID=33555491

Family Applications (1)

Application Number Title Priority Date Filing Date
IL172496A IL172496A (en) 2003-06-13 2005-12-11 Encoding Nucleic Acid Sequences and Compounds Containing IgE and / or 15-IL Peptide and Methods for Their Use

Country Status (12)

Country Link
US (2) US8173786B2 (fr)
EP (2) EP2292634A3 (fr)
JP (2) JP2007516696A (fr)
KR (2) KR101225473B1 (fr)
CN (1) CN1832956B (fr)
AU (2) AU2004251070B2 (fr)
BR (1) BRPI0411363A (fr)
CA (1) CA2529145C (fr)
IL (1) IL172496A (fr)
MX (1) MXPA05013526A (fr)
NZ (2) NZ570709A (fr)
WO (1) WO2005000235A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
JP5346588B2 (ja) 2006-01-13 2013-11-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア コドン最適化したｉｌ−１５を用いるワクチンおよび免疫治療とその使用方法
CN105132439A (zh) 2006-07-28 2015-12-09 宾夕法尼亚大学托管会 改进的疫苗及其使用方法
US10426827B1 (en) * 2006-11-06 2019-10-01 Microvax, Llc Dengue hemorrhagic fever virus vaccine
KR101686942B1 (ko) * 2008-01-11 2016-12-28 이노비오 파마수티컬즈, 인크. 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신
WO2009124312A2 (fr) * 2008-04-04 2009-10-08 The Trustees Of The University Of Pennsylvania Séquences consensus de protéines du virus chikungunya, molécules d’acide nucléique codant pour celles-ci, et compositions et procédés d’utilisation de celles-ci
WO2009124309A2 (fr) * 2008-04-04 2009-10-08 The Trustees Of The University Of Pennsylvania Vaccins et produits immunothérapeutiques utilisant de l’il-28 et compositions et procédés pour leur utilisation
KR20120093163A (ko) 2009-09-14 2012-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
AU2011213559B2 (en) 2010-02-08 2015-05-07 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
CA2827080C (fr) 2011-02-11 2022-09-20 The Trustees Of The University Of Pennsylvania Molecule d'acide nucleique codant la proteine centrale du virus de l'hepatite b et vaccin la comprenant
KR20140116095A (ko) 2011-12-12 2014-10-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Mrsa pbp2a 및 이의 단편들을 포함하는 단백질, 이를 인코딩한 핵산, 및 mrsa 감염을 예방 및 치료하기 위한 조성물 및 그의 용도
AU2013245950B2 (en) 2012-04-10 2016-04-21 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
KR102146904B1 (ko) * 2012-04-12 2020-08-24 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
CN105408473B9 (zh) 2013-05-14 2021-09-17 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
EP3105335B1 (fr) 2014-02-14 2019-10-02 Board Of Regents, The University Of Texas System Récepteurs antigéniques chimériques et procédé de production
KR102586707B1 (ko) * 2014-10-01 2023-10-11 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항원 및 어쥬번트로서 인터류킨-21을 갖는 백신
CN108472354A (zh) * 2015-10-22 2018-08-31 摩登纳特斯有限公司 呼吸道合胞病毒疫苗
EA201892124A1 (ru) 2016-12-02 2019-04-30 Дэвид Б. Уэйнер Днк-конструкции антител и способы их применения
CU24546B1 (es) * 2016-12-30 2021-09-07 Ct Ingenieria Genetica Biotecnologia Composición vacunal que comprende un mutante de la interleucina-15 humana
AU2018207281B2 (en) 2017-01-10 2024-08-01 Precigen, Inc. Modulating expression of polypeptides via new gene switch expression systems
CA3081436A1 (fr) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Vecteur de plateforme oncolytique pour administration systemique
RU2751252C1 (ru) 2017-12-13 2021-07-12 Иновио Фармасьютикалз, Инк. Мезотелин-нацеленные вакцины от рака и их применение
US20220332780A1 (en) 2019-09-10 2022-10-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
US12064481B2 (en) * 2020-11-02 2024-08-20 Drexel University Compositions and methods employing adenosine deaminase-1 (ADA-1) as an adjuvant
JP2024516400A (ja) * 2021-04-30 2024-04-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 修飾されたｍｈｃ発現のための腫瘍溶解性ウイルス

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2157994A (en) 1937-11-08 1939-05-09 Kelsey Hayes Wheel Co Brake mechanism
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
JP3044062B2 (ja) 1989-03-08 2000-05-22 ヘルス・リサーチ・インク 組換えポックスウイルス宿主選択系
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU645489B2 (en) 1989-03-31 1994-01-20 Washington University Vaccines containing avirulent phoP-type microorganisms
EP0431668B1 (fr) 1989-12-04 1995-02-15 Akzo Nobel N.V. Virus herpès de dinde recombinant et vaccins-vecteurs vivants dérivés de celui-ci
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
NZ262582A (en) 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
EP1243597B1 (fr) 1995-08-01 2008-07-09 F. Hoffmann-La Roche Ag Récepteurs pour l'interleukine-12 humaine
AU729579B2 (en) * 1996-10-23 2001-02-01 Trustees Of The University Of Pennsylvania, The Immunotherapy and improved vaccines
WO1999016466A2 (fr) * 1997-09-29 1999-04-08 Beth Israel Deaconess Medical Center Compositions de vaccin et procedes servant a augmenter l'efficacite d'un vaccin
CA2313805A1 (fr) * 1997-12-19 1999-07-01 Immunex Corporation Procede pour reduire la sensibilite a l'infection a vih
EP1053343A2 (fr) * 1998-02-11 2000-11-22 Maxygen, Inc. Ciblage de vecteurs de vaccins genetiques
US7560105B1 (en) 1999-10-04 2009-07-14 Leids Universitair Medisch Centrum Dendritic cells activated in the presence of glucocorticoid hormones are capable of suppressing antigen-specific T cell responses
ATE371722T1 (de) 2000-05-11 2007-09-15 Baylor Res Inst Zusammensetzungen und verfahren zur herstellung von antigen-präsentierenden zellen
US6733994B2 (en) * 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
ATE531390T1 (de) 2001-08-23 2011-11-15 Genmab As Interleukin-15-(il-15-)spezifische menschliche antikörper
AU2003243663A1 (en) * 2002-06-20 2004-01-06 The Trustees Of The University Of Pennsylvania Vaccines for suppressing ige-mediated allergic disease and methods for using the same
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Also Published As

Publication number Publication date
AU2004251070A1 (en) 2005-01-06
CN1832956B (zh) 2013-11-20
AU2004251070B2 (en) 2012-02-23
KR20060030041A (ko) 2006-04-07
US20070041941A1 (en) 2007-02-22
EP1638987A2 (fr) 2006-03-29
MXPA05013526A (es) 2006-03-09
CA2529145A1 (fr) 2005-01-06
EP1638987A4 (fr) 2007-12-26
CN1832956A (zh) 2006-09-13
JP2012110345A (ja) 2012-06-14
KR20110129945A (ko) 2011-12-02
NZ570709A (en) 2010-04-30
IL172496A0 (en) 2006-04-10
WO2005000235A3 (fr) 2005-06-16
JP5623444B2 (ja) 2014-11-12
US8173786B2 (en) 2012-05-08
KR101225473B1 (ko) 2013-01-24
BRPI0411363A (pt) 2006-07-25
EP1638987B1 (fr) 2014-11-19
US20120276142A1 (en) 2012-11-01
EP2292634A2 (fr) 2011-03-09
EP2292634A3 (fr) 2012-08-08
JP2007516696A (ja) 2007-06-28
AU2012202867B2 (en) 2015-01-29
CA2529145C (fr) 2017-07-11
NZ544077A (en) 2009-01-31
KR101269548B1 (ko) 2013-06-21
WO2005000235A2 (fr) 2005-01-06
AU2012202867A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
AU2012202867B2 (en) Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
AU759603B2 (en) Vaccines, immunotherapeutics and methods for using the same
US11998598B2 (en) Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
US9278128B2 (en) Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
WO2002100345A2 (fr) Vaccins, compositions immunotherapeutiques, et procedes d'utilisation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed